menu
    • menu
    [{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"California Institute for Regenerative Medicine (CIRM)","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ California Institute for Regenerative Medicine (CIRM)","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ California Institute for Regenerative Medicine (CIRM)"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MDR-102","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MDR-103","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medeor Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Medeor Therapeutics

    Menu

    Medeor Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medeor Therapeutics Announces Interim Data from Pivotal Trial Showing Cell Therapy Technology Could Eliminate ...

                            Details : MDR-101, is a single-dose cellular therapy derived from a living kidney donor’s blood. The therapy is designed to establish mixed chimerism, which occurs when a low level of donor blood cells remains in the blood of the kidney recipient after infusion ...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 02, 2023

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medeor Therapeutics to Provide Interim Results of Phase 3 Mercury Study of MDR-101 Cell Therapy in Living Dono...

                            Details : MDR-101 is a single-dose cellular therapy derived from a living kidney donor’s blood. This is the first randomized, multi-center pivotal study specifically designed to eliminate the use of immunosuppressive anti-rejection drugs following transplant.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 20, 2021

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medeor Completes Enrollment and Transplantation for Pivotal Trial of MDR-101 Cell Therapy for HLA-Matched Dono...

                            Details : MDR-101 is intended to induce donor-specific immune tolerance in order to avert transplant kidney rejection to minimize cumulative and serious side effects associated with immunosuppressive drugs.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 12, 2021

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medeor Therapeutics Announces Data Presentation at the American Society of Nephrology Kidney Week 2020

                            Details : The presentation will review the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 30, 2020

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medeor Therapeutics’ Transplant Immune Tolerance Therapy Receives Regenerative Medicine Advanced Therapy Des...

                            Details : MDR-101 is being developed to avert transplant kidney rejection by the recipient’s immune system without the need for chronic use of immunosuppressive drugs.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 22, 2020

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDR-103

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Trans...

                            Details : MDR-103 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graft Rejection.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 31, 2018

                            Lead Product(s) : MDR-103

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDR-102

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transpla...

                            Details : MDR-102 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Graft Rejection.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 30, 2018

                            Lead Product(s) : MDR-102

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Medeor Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : California Institute for Regenerative Medicine (CIRM)

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

                            Details : MDR-101 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft Rejection.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 06, 2017

                            Lead Product(s) : MDR-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : California Institute for Regenerative Medicine (CIRM)

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth